Researchers sought to determine 1-year outcomes in patients being treated with tirzepatide who have atrial fibrillation.

Boston Scientific, Medtronic, Abbott and J&J unveiled new data for their PFA devices in tandem with the Heart Rhythm ...

The benefit of GLP-1 therapy couldn’t be explained by weight loss, suggesting that some pleiotropic effects may be at work.

Abbott has reported new data from its prospective, non-randomised Volt CE Mark Study, indicating that individuals treated ...

A system hybridizing cardiac contractility modulation and implantable cardioverter defibrillation successfully converted ...

“It was an experience that dramatically improved my life,” said Mike Prescott of Kenosha, who retired a couple of years ago ...

Emerging pulsed field ablation systems had their moments in the spotlight at the annual meeting of the Heart Rhythm Society ...

Patients with a high probability of HFpEF may experience greater benefits from atrial fibrillation ablation than those with a ...

GLP-1 use significantly lowered risk for atrial fibrillation-related events for patients with diabetes, AF and obesity, with ...

For patients newly diagnosed with atrial fibrillation (AF) during hospitalization for other causes, most are not dispensed ...